Lugano, Switzerland, and Osaka, Japan, January 22, 2021 - Helsinn Group (Lugano, Switzerland; CEO: Riccardo Braglia, “Helsinn”) and Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and Representative Director: Gyo Sagara; “ONO”) announced today that ONO received the manufacturing and marketing approval of Adlumiz® (generic name: anamorelin hydrochloride) Tablet 50mg (“Adlumiz”), a ghrelin receptor agonist, for the treatment of cancer cachexia in malignant tumors of non-small cell lung cancer, gastric cancer, pancreatic cancer or colorectal cancer in Japan.